STOCK TITAN

Sonnet Biotherapeutc Hldng Inc - SONN STOCK NEWS

Welcome to our dedicated page for Sonnet Biotherapeutc Hldng news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet Biotherapeutc Hldng stock.

Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) is a clinical-stage biotechnology innovator developing targeted immunotherapies through its proprietary FHAB platform. This page serves as the definitive source for verified company announcements, including clinical trial updates, regulatory milestones, and strategic developments in immuno-oncology.

Investors and researchers will find timely updates on SONN's pipeline progress, including its lead candidates targeting cancer and immune-mediated conditions. Our curated news collection features press releases about FHAB technology advancements, partnership announcements, and financial disclosures – all essential for tracking this innovative biotech's trajectory.

The repository systematically organizes updates across key categories: new patent filings, preclinical data publications, Phase 1 trial results, and executive team developments. Each entry maintains strict editorial standards to ensure compliance with financial reporting regulations.

For those monitoring advancements in bispecific antibody therapies and tumor microenvironment modulation, this resource offers structured access to SONN's scientific and corporate developments. Bookmark this page for efficient tracking of how the company's platform-based approach translates to clinical progress and strategic positioning within the competitive oncology landscape.

Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ:SONN) announced a collaboration with Janssen Biotech to evaluate its products SON-1010, SON-1210, and SON-1410. The evaluation will focus on in vitro and in vivo efficacy in preclinical models, leveraging Janssen's proprietary cell therapy assets. If successful, Sonnet may pursue an expanded collaboration. This represents Sonnet's first head-to-head evaluation, which could inform oncology indications and potentially lead to a license agreement, as stated by CEO Pankaj Mohan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
66.38%
Tags
none
-
Rhea-AI Summary

Sonnet BioTherapeutics Holdings announced it has regained compliance with Nasdaq's minimum bid price requirement, meeting the $1.00 bid price for 10 consecutive trading days by September 30, 2022. However, the company is still not compliant with the stockholders' equity requirement of $2.5 million, having received a notice from Nasdaq on August 22, 2022. Sonnet has until October 6, 2022, to submit a plan to regain compliance, which, if accepted, could grant an extension of up to 180 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
none
-
Rhea-AI Summary

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has appointed Lori McNeill to its Board of Directors, also making her the Chairperson of the newly established Business Advisory Committee (BAC). With over 20 years in healthcare and a background at Pfizer, McNeill is expected to enhance Sonnet's strategic collaborations and communication efforts, particularly regarding government initiatives like the Cancer Moonshot. The BAC will guide the company on external partnerships and elevate its profile in immune oncology, coinciding with upcoming clinical trial data releases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.15%
Tags
management
Rhea-AI Summary

On September 21, 2022, Sonnet BioTherapeutics Holdings announced progress in their Phase 1 clinical trials for SON-1010 (IL-12-FHAB), having dosed 19 subjects so far. The initial safety review has cleared the way for continued dose escalation. SB101 focuses on advanced solid tumors, while SB102 involves healthy volunteers. No dose-limiting toxicities have been reported. Upcoming data on safety and cytokine-specific responses is expected in Q4 2022. This development marks a significant milestone in immunotherapy, with SON-1010 aiming to enhance safety and efficacy in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.58%
Tags
-
Rhea-AI Summary

Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced a 1-for-14 reverse stock split effective September 19, 2022. The split aims to elevate the share price above the $1.00 minimum for continued Nasdaq listing. Post-split, shares will decrease from approximately 69.6 million to 5.0 million. The initiative was approved by stockholders on September 15, 2022, and will also impact outstanding warrants and options. No fractional shares will be issued; cash payments will be provided instead for fractional interests. The par value remains at $0.0001 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.04%
Tags
none
-
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ:SONN) announced the initiation of clinical trials for SON-1010 and SON-080, targeting advanced solid tumors and chemotherapy-induced peripheral neuropathy, respectively. Positive preclinical data supports SON-1010’s combination with anti-PD1 therapy.

Financially, Sonnet reported $5.2 million cash on hand, with R&D expenses rising to $5.6 million. Additionally, the company launched a $6.1 million at-the-market offering and completed a private placement raising $2.25 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.34%
Tags
Rhea-AI Summary

Sonnet BioTherapeutics announced the initiation of a Phase 1b/2a clinical trial for SON-080, a treatment targeting persistent chemotherapy-induced peripheral neuropathy (CIPN). The trial, authorized for multiple sites in Australia, aims to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD), with dosing expected soon. SON-080 is a proprietary form of recombinant human interleukin-6 (rhIL-6), anticipated to promote nerve regrowth and alleviate CIPN symptoms. Successful results may lead to further development for diabetic peripheral neuropathy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
-
Rhea-AI Summary

Sonnet BioTherapeutics announced the initiation of a second Phase 1 clinical trial for SON-1010 (IL12-FHAB) after successfully starting its first trial. This new study will provide important pharmacokinetic (PK) and pharmacodynamic (PD) data, focusing on safety and tolerability in healthy volunteers in Australia. SON-1010 utilizes the F technology to enhance delivery to tumors. The trial aims to inform further potential applications of SON-1010 while expanding on its foundational bispecific molecule research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ:SONN) reported promising preclinical data indicating that SON-1010 (IL12-FHAB) combined with a commercially available anti-PD1 antibody led to significant tumor growth inhibition in a melanoma model. The combination resulted in a 79.1% inhibition rate compared to a placebo group and improved survival rates, with seven out of nine mice surviving the combination treatment. These results highlight the potential of SON-1010 in enhancing checkpoint inhibitor efficacy, aiding future study designs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
Rhea-AI Summary

Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced the adjournment of its 2022 Annual Meeting due to lack of quorum. The meeting, originally held on June 2, 2022, will reconvene on June 23, 2022, at 9:00 a.m. ET. Only 46% of outstanding shares entitled to vote were represented. Stockholders of record as of April 4, 2022, are encouraged to vote by June 22, 2022. The company aims to finalize voting on proposals outlined in its proxy statement filed on April 12, 2022. The Board recommends voting in favor of all proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
Sonnet Biotherapeutc Hldng Inc

Nasdaq:SONN

SONN Rankings

SONN Stock Data

3.86M
3.02M
1.58%
3.06%
3.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON